S.C.P.C (1720) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 生達

S.C.P.C (1720) reported revenue of NT$619 million for Oct 2026, -3.5% year on year and -11.5% from the previous month. Revenue for Jan–Oct 2026 was NT$6.06 billion (+3.2% year on year).

In Oct 2026, it ranked No. 14 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$536.9 million24/10Nov 2024 NT$595.1 millionDec 2024 NT$539.9 millionJan 2025 NT$527.5 millionFeb 2025 NT$557.8 million25/02Mar 2025 NT$554.7 millionApr 2025 NT$652.5 millionMay 2025 NT$611.7 millionJun 2025 NT$563.7 million25/06Jul 2025 NT$561.5 millionAug 2025 NT$578.7 millionSep 2025 NT$629.4 millionOct 2025 NT$641.2 million25/10Nov 2025 NT$578 millionDec 2025 NT$565.8 millionJan 2026 NT$614.9 millionFeb 2026 NT$466.1 million26/02Mar 2026 NT$570.2 millionApr 2026 NT$677.3 millionMay 2026 NT$581 millionJun 2026 NT$615 million26/06Jul 2026 NT$597.2 millionAug 2026 NT$623.7 millionSep 2026 NT$699.6 millionOct 2026 NT$619 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$619 million-3.5%-11.5%
Sep 2026NT$699.6 million+11.2%+12.2%
Aug 2026NT$623.7 million+7.8%+4.4%
Jul 2026NT$597.2 million+6.4%-2.9%
Jun 2026NT$615 million+9.1%+5.9%
May 2026NT$581 million-5.0%-14.2%
Apr 2026NT$677.3 million+3.8%+18.8%
Mar 2026NT$570.2 million+2.8%+22.3%
Feb 2026NT$466.1 million-16.4%-24.2%
Jan 2026NT$614.9 million+16.6%+8.7%
Dec 2025NT$565.8 million+4.8%-2.1%
Nov 2025NT$578 million-2.9%-9.9%
Oct 2025NT$641.2 million+19.4%+1.9%
Sep 2025NT$629.4 million+9.0%+8.8%
Aug 2025NT$578.7 million-2.3%+3.1%
Jul 2025NT$561.5 million-2.1%-0.4%
Jun 2025NT$563.7 million+0.2%-7.8%
May 2025NT$611.7 million+2.6%-6.3%
Apr 2025NT$652.5 million+8.6%+17.6%
Mar 2025NT$554.7 million+5.4%-0.6%
Feb 2025NT$557.8 million+25.4%+5.8%
Jan 2025NT$527.5 million-17.9%-2.3%
Dec 2024NT$539.9 million+7.3%-9.3%
Nov 2024NT$595.1 million+2.3%+10.8%
Oct 2024NT$536.9 million+5.4%-7.0%

Jan–Oct 2026 cumulative: NT$6.06 billion (+3.2% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: S.C.P.C vs PEC / S.C.P.C vs Lotus Pharm / S.C.P.C vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16